PharmaEngine, Inc. (TPEX: 4162)

Market Cap	13.86B
Revenue (ttm)	831.92M
Net Income (ttm)	370.14M
Shares Out	143.68M
EPS (ttm)	2.57
PE Ratio	37.55
Forward PE	11.65
Dividend	1.50 (1.56%)
Ex-Dividend Date	Aug 12, 2024

Volume	1,372,781
Open	101.50
Previous Close	101.50
Day's Range	99.90 - 103.00
52-Week Range	74.80 - 115.00
Beta	0.65
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 25, 2024

About PharmaEngine

PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan and Europe. It offers ONIVYDE, a novel and stable encapsulated chemotherapy drug irinotecan for the treatment of metastatic pancreatic cancer and other indications of clinical development. The company is developing PEP07, a checkpoint kinase 1 inhibitor, which is in preclinical development stage for the treatment of hematologic cancers and solid cancers, such as acute myeloid leukemia and mantle cell lymphoma....

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 4162

Financial Performance

In 2023, PharmaEngine's revenue was 767.67 million, an increase of 17.31% compared to the previous year's 654.38 million. Earnings were 274.65 million, a decrease of -13.84%.